Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.42 |
| ▸ | ACP1 | P24666 | 8/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31321767 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ANPSR1PTPN1 | |
| SCHEMBL31321760 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ANPSR1PPARA | |
| SCHEMBL31321764 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ANPSR1PTPN1 | |
| SCHEMBL31321771 | 0.81 | PTPN1 (0.66) | ALDH1A1MEN1KMT2ANPSR1PTPN1 | |
| SCHEMBL31321765 | 0.79 | PTPN1 (0.66) | ALDH1A1MEN1KMT2ANPSR1PTPN1 | |
| SCHEMBL31321761 | 0.79 | PTPN1 (0.57) | ALDH1A1MEN1KMT2ANPSR1PTPN1 | |
| SCHEMBL31321768 | 0.78 | PTPN1 (0.67) | ALDH1A1MEN1KMT2ANPSR1PTPN1 | |
| SCHEMBL31321766 | 0.77 | PTPN1 (0.49) | ALDH1A1MEN1KMT2ANPSR1POLB | |
| SCHEMBL31321758 | 0.76 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2ANPSR1POLB | |
| SCHEMBL31321773 | 0.76 | PTPN1 (0.48) | ALDH1A1MEN1KMT2ANPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145930-B1 | 4-thiazolidinone derivatives as EGFR inhibitors for anti-tumor activity | King Faisal University (SA) | 2024-11-19 | — | — | US | claimed |
| US-12145930-B1 | 4-thiazolidinone derivatives as EGFR inhibitors for anti-tumor activity | King Faisal University (SA) | 2024-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145930-B1 | 4-thiazolidinone derivatives as EGFR inhibitors for anti-tumor activity | EGFR, ERBB4, ERBB2 | ALDH1A1 1409/4885MEN1 3323/4885KMT2A 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.